Innoviva (INVA) Non Operating Income (2013 - 2026)
Innoviva (INVA) reported Non Operating Income of -$366000.0 for Q1 2026, up 63.25% on a YoY basis from -$224191.9 in Q1 2025, and up 23.59% quarter-over-quarter from -$479000.0 in Q3 2025.
Innoviva (INVA) Non Operating Income (2013 - 2026) Analysis & Trends
Innoviva has reported Non Operating Income for 14 years, with the latest figure at -$366000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 63.25% year-over-year to -$366000.0; the trailing twelve-month figure through Mar 2026 stood at -$2.6 million (up 36.44% YoY), and the FY2025 full-year result was -$2.9 million, up 4.44% from the prior year.
- Non Operating Income for Q1 2026 stood at -$366000.0, up from -$479000.0 in the prior quarter.
- The five-year high for Non Operating Income was $28000.0 in Q3 2022, with the low at -$1.9 million in Q2 2023.
- Historically, Non Operating Income has averaged -$829230.8 across 5 years, with a median of -$914000.0 in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 104.29% — and 2023, when it sank 3839.29%.
- Innoviva's Non Operating Income stood at $28000.0 in 2022, then slumped by 3839.29% to -$1.0 million in 2023, then rose by 12.7% to -$914000.0 in 2024, then jumped by 47.59% to -$479000.0 in 2025, then grew by 23.59% to -$366000.0 in 2026.
- The last three Non Operating Income figures came in at -$366000.0 (Q1 2026), -$479000.0 (Q3 2025), and -$777000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Innoviva | 1.65 Bn | 1.05 Bn | 75.83 Mn | -366,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -366,000.00 |
| Sep 30, 2025 | -479,000.00 |
| Jun 30, 2025 | -777,000.00 |
| Mar 31, 2025 | -996,000.00 |
| Sep 30, 2024 | -914,000.00 |
| Jun 30, 2024 | -973,000.00 |
| Mar 31, 2024 | -1.24 Mn |
| Sep 30, 2023 | -1.05 Mn |
| Jun 30, 2023 | -1.90 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Sep 30, 2022 | 28,000.00 |
| Jun 30, 2022 | -528,000.00 |
| Mar 31, 2022 | -250,000.00 |
| Sep 30, 2021 | -652,000.00 |
| Jun 30, 2021 | -951,000.00 |
| Mar 31, 2021 | -433,000.00 |
| Dec 31, 2020 | -433,000.00 |
| Sep 30, 2020 | -13,000.00 |
| Jun 30, 2020 | 30,000.00 |
| Mar 31, 2020 | 68,000.00 |